US contractor upholds Pacific Edge's Medicare ban

US contractor upholds Pacific Edge's Medicare ban
Pacific Edge has had a fresh blow to its hopes for access to the US Medicare market for Cxbladder diagnostic tests. (Image: Pacific Edge)
Greg Hurrell
Pacific Edge’s flagship Cxbladder cancer testing has been deemed as “not considered medically reasonable and necessary” by the company’s United States Medicare administrator. The statement is in a new proposed Local Coverage Determination (LCD) for Medicare and is a fresh blow for the company’s hopes to quickly regain long-term access to the Medicare system for its bladder cancer tests.Medicare is Pacific Edge’s largest customer.The new LCD was released overnight New Zealand time by Novitas, Pacific Edge...

More Markets

Listed property firms welcome ‘Investment Boost'
Property

Listed property firms welcome ‘Investment Boost'

The tax policy could translate into millions in extra cash.

Drury’s ASX stag, MetroGlass’s new owner, and more
Markets Small Cap Wrap

Drury’s ASX stag, MetroGlass’s new owner, and more

Rod Drury goes ‘pre-revenue’ again, plus small cap news from NZ.

NZX down as property company gets key renewal
Markets Market Close

NZX down as property company gets key renewal

ASB Bank has extended the lease for its downtown Auckland site for another nine years.

Tom Raynel 03 Jul 2025
Anna Scott joining Mercer
Markets

Anna Scott joining Mercer

Former Smart boss will replace current Mercer chief executive Martin Lewington.

Staff reporters 03 Jul 2025